Table 2.

Selected baseline characteristics BENCHMRK-1 and -2 trials

	BENCHMRK-1		BENCHMRK-2
	Raltegravir	Placebo	Raltegravir	Placebo
n	232	118	230	119
Age	46.1	43.7	45.3	46.5
Male	84.1%	87.3%	91.3%	89.9%
Baseline CD4 count (mean)	156.4	152.8	146.4	163.2
Baseline HIV-1 RNA (mean) log10 copies/mL	4.6	4.5	4.7	4.7
AIDS diagnosis	93.5%	89.8%	90.9%	92.4%
Prior antiretroviral use in years (median)	10.6	10.3	9.6	10.1
Number of antiretrovirals used in the past	12	12	12	12
Enfurvitidea in optimized background regimen	37.9%	36.4%	37.8%	38.7%
Resistance to ≥PIs	97%	94.9%	96.5%	95.8%

Derived from Isentress FDA Briefing Document 2007.

^aIncludes those already enfuvirtide experienced.

Abbreviation: PIs, protease inhibitors.